Page 1 | Search Results | The Hematologist | American Society of Hematology

Skip Nav Destination

1-9 of 9

Sort by

Sort Order Select

Articles

Targeting Telomerase in Lower-risk Myelodysplastic Syndromes

Christine M. Mcmahon, MD

The Hematologist (2024) 21 (2)

https://doi.org/10.1182/hem.V21.2.2024218

Published: 2024

Articles

COMMANDing Anemia in Lower-risk Myelodysplastic Syndromes: Luspatercept Versus Erythropoiesis-stimulating Agents

Christine M. McMahon, MD

The Hematologist (2023) 20 (6)

https://doi.org/10.1182/hem.V20.6.202364

Published: 2023

Articles

MEN1 Mutations Induce Acquired Resistance to the Menin Inhibitor Revumenib

Christine M. McMahon, MD

The Hematologist (2023) 20 (5)

https://doi.org/10.1182/hem.V20.5.2023510

Published: 2023

Articles

Gene Therapy for Germline Predisposition to Myeloid Malignancies: Insights from a Nonhuman Primate RUNX1 Model

Christine M. McMahon, MD

The Hematologist (2023) 20 (3)

https://doi.org/10.1182/hem.V20.3.2023313

Published: 2023

Articles

Not Just Caused by Getting Old: Germ Line Predisposition Identified in Patients of All Ages with Myelodysplastic Syndrome

Christine M. McMahon, MD

The Hematologist (2023) 20 (2)

https://doi.org/10.1182/hem.V20.2.2023210

Published: 2023

Articles

Menin Inhibitors: A Promising Class of Targeted Therapies for KMT2A -rearranged and NPM1 -mutated Acute Leukemias

Christine M. McMahon, MD

The Hematologist (2022) 19 (5)

https://doi.org/10.1182/hem.V19.5.2022513

Published: 2022

Articles

Targeting AML in Unfit Patients: Ivosidenib/Azacitidine for IDH1 -mutated AML

Alexander G. Hayden, MD, Christine M. McMahon, MD

The Hematologist (2022) 19 (4)

https://doi.org/10.1182/hem.V19.4.202242

Published: 2022

Articles

Toward Understanding Disparities in AML Outcomes: The Role of Structural Racism

Christine M. McMahon, MD

The Hematologist (2022) 19 (3)

https://doi.org/10.1182/hem.V19.3.202239

Published: 2022

Articles

STAMPing on BCR-ABL1: Asciminib Approved for Chronic Myeloid Leukemia

Christine M. McMahon, MD

The Hematologist (2022) 19 (2)

https://doi.org/10.1182/hem.V19.2.202221

Published: 2022

NARROW

Targeting Telomerase in Lower-risk Myelodysplastic Syndromes

COMMANDing Anemia in Lower-risk Myelodysplastic Syndromes: Luspatercept Versus Erythropoiesis-stimulating Agents

MEN1 Mutations Induce Acquired Resistance to the Menin Inhibitor Revumenib

Gene Therapy for Germline Predisposition to Myeloid Malignancies: Insights from a Nonhuman Primate RUNX1 Model

Not Just Caused by Getting Old: Germ Line Predisposition Identified in Patients of All Ages with Myelodysplastic Syndrome

Menin Inhibitors: A Promising Class of Targeted Therapies for KMT2A -rearranged and NPM1 -mutated Acute Leukemias

Targeting AML in Unfit Patients: Ivosidenib/Azacitidine for IDH1 -mutated AML

Toward Understanding Disparities in AML Outcomes: The Role of Structural Racism

STAMPing on BCR-ABL1: Asciminib Approved for Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only